Patents by Inventor Pedro Anastacio Serrano-Ojeda

Pedro Anastacio Serrano-Ojeda has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11890265
    Abstract: The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Grant
    Filed: March 25, 2019
    Date of Patent: February 6, 2024
    Assignee: SERBIG PHARMACEUTICALS CORPORATION
    Inventor: Pedro Anastacio Serrano-Ojeda
  • Patent number: 11452776
    Abstract: The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Grant
    Filed: September 24, 2019
    Date of Patent: September 27, 2022
    Assignee: SERBIG PHARMACEUTICALS CORP.
    Inventor: Pedro Anastacio Serrano-Ojeda
  • Publication number: 20200261579
    Abstract: The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Application
    Filed: September 24, 2019
    Publication date: August 20, 2020
    Applicant: SERBIG PHARMACEUTICALS CORP.
    Inventor: Pedro Anastacio SERRANO-OJEDA
  • Patent number: 10456469
    Abstract: The present invention is a glutamine compound having a non-radioisotope high Z element attached via a linker, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Grant
    Filed: March 3, 2017
    Date of Patent: October 29, 2019
    Assignee: SERBIG PHARMACEUTICALS CORP.
    Inventor: Pedro Anastacio Serrano-Ojeda
  • Publication number: 20190216758
    Abstract: The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Application
    Filed: March 25, 2019
    Publication date: July 18, 2019
    Inventor: Pedro Anastacio Serrano-Ojeda
  • Patent number: 10292956
    Abstract: The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Grant
    Filed: September 21, 2015
    Date of Patent: May 21, 2019
    Assignee: Serbig Pharmaceutics Corp.
    Inventor: Pedro Anastacio Serrano-Ojeda
  • Publication number: 20190076527
    Abstract: The present invention is a glutamine compound having a non-radioisotope high Z element attached via a linker, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Application
    Filed: March 3, 2017
    Publication date: March 14, 2019
    Applicant: SERBIG PHARMACEUTICALS CORP.
    Inventor: Pedro Anastacio SERRANO-OJEDA
  • Publication number: 20170173155
    Abstract: The present invention is a glutamine compound having a non-radioisotope high Z element attached via a linker, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Application
    Filed: March 3, 2017
    Publication date: June 22, 2017
    Inventor: Pedro Anastacio SERRANO-OJEDA
  • Publication number: 20160058728
    Abstract: The present invention is a glutamine compound having a high Z element attached via a ligand, which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Application
    Filed: September 21, 2015
    Publication date: March 3, 2016
    Inventor: Pedro Anastacio Serrano-Ojeda
  • Publication number: 20110054019
    Abstract: The present invention is a glutamine analogue which enters the mitochondrion and is subsequently exposed to ionizing radiation. When exposed to ionizing radiation, the present invention damages mitochondrial (as well as other) substructures such as mtDNA, the outer membrane, the inner membrane, cristae, ribosomes, etc., and causes the effective destruction of such mitochondrion. Tumorigenic cells without mitochondria cannot produce the energy they need to subsist and replicate, effectively starving them of energy and causing their destruction.
    Type: Application
    Filed: September 1, 2009
    Publication date: March 3, 2011
    Inventor: Pedro Anastacio Serrano-Ojeda